A method for constructing a non-human primate autism model
By injecting AAV-SaCas9-MECP2 knockout virus using 7T magnetic resonance scanning imaging technology in marmosets, knocking out MECP2 gene, and establishing autism model in marmosets, solving the long construction cycle of non-human primate models and the inability to form a genealogy. The problem provides new research models and drug screening tools to gain insight into the pathogenesis of autism and provide new avenues for treatment.
Patent Information
- Application Number
- CN202410291497.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-14
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-03-14
AI Technical Summary
The construction of autism models in non-human primates in the prior art has defects such as long experimental cycles and inability to form a genealogy, and it is difficult to deeply reveal the pathogenic mechanism of autism.
The 7T magnetic resonance scanning imaging technology was used to accurately locate the prefrontal area of the marmoset brain of marmoset monkeys and inject AAV-SaCas9-MECP2 knockout virus to establish a model of autism in marmoset monkeys. The MECP2 gene was knocked out through CRISPR-Cas9 gene editing technology, and the marmoset monkeys were induced to produce loneliness. The core symptoms of spectrum disorder - language communication disorder, and is evaluated through acoustic behavioral tests.
It has realized the construction of experimental subjects with the same genetic conditions in marmosets, overcome the shortcomings of the construction of autism models in the existing technology, provided new research models and drug screening tools, and gained insight into the occurrence of autism. mechanisms and provide new avenues for treatment.
Smart Images

Figure CN118186006B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a method for constructing a non-human primate autism model. Background Art
[0002] Autism Spectrum Disorder (ASD) is a highly heritable neurodevelopmental disorder. Patients usually show problems with sociality, communication, language skills, and ritualized stereotyped behaviors. In recent years, the prevalence of autism spectrum disorder has increased year by year, placing a huge burden on patients, their families, and society. However, due to the complex causes of autism and unclear pathogenic mechanisms, there is still no effective treatment.
[0003] At present, the research on human ASD patients is mainly non-invasive research with low temporal and spatial resolution, which makes it difficult to deeply reveal the pathogenic mechanism. Therefore, the construction of animal models of autism is particularly important. Rodents are widely used in autism modeling research, but because they are far from human relatives, the size and complexity of their brains cannot be compared with humans, and it is questionable whether they can accurately simulate complex mental illnesses such as autism. Non-human primates have a high genetic homology with humans, and their brain structure and function are similar to those of humans. They are also similar in social attributes and are good animal models for social dysfunction diseases. ASD research using non-human primates as experimental subjects has also made some progress. For example, macaques with overexpression of the MECP2 gene and macaques with mutations in the SHANK3 gene both show autism-like symptoms such as repetitive stereotyped behaviors and social behavior disorders. However, macaques are single-born offspring breeding, and their breeding cycle is long. Therefore, the construction of autism models with non-human primates still has defects such as long experimental cycles and the inability of experimental subjects to form a pedigree, which need to be solved. Summary of the invention
[0004] In order to solve the above technical problems, the present invention proposes a method for constructing a non-human primate autism model. The marmoset autism model is established by precisely injecting AAV-SaCas9-MECP2 knockout virus into the prefrontal lobe area of the marmoset brain using 7T magnetic resonance imaging technology (MRI).
[0005] To achieve the above object, the present invention provides a method for constructing a non-human primate autism model, comprising the following steps:
[0006] (1) Locating the prefrontal lobe region of a non-human primate; (2) Injecting AAV-SaCas9-MECP2 knockout virus solution into the prefrontal lobe region of the brain described in step (1); (3) Performing behavioral testing on the non-human primate 8 weeks after injection of the AAV-SaCas9-MECP2 knockout virus solution.
[0007] Preferably, the non-human primate is a marmoset.
[0008] Preferably, the positioning in step (1) uses 7T magnetic resonance scanning imaging technology.
[0009] Preferably, the injection depth in step (2) is 1.5 to 3.5 mm, the injection speed is 150 nL / min, and there are 6 injection points.
[0010] Preferably, the AAV-SaCas9-MECP2 knockout virus solution in step (2) includes AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution, AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution and AAV9-hSyn-GFP virus solution; the injection volume of the AAV-SaCas9-MECP2 knockout virus solution at each injection point is 3 μL.
[0011] Further preferably, the volume ratio of AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution, AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution and AAV9-hSyn-GFP virus solution in the AAV-SaCas9-MECP2 knockout virus solution is 4:4:2; the titer of the AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution is 1.12×10 13 VG / mL; the titer of the AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution is 1.64×10 13 VG / mL; the titer of the AAV9-hSyn-GFP virus solution is 2.18×10 13 VG / mL.
[0012] Preferably, the behavioral test in step (3) is a solitary social interaction test and an interactive vocal social interaction test, and the non-human primate autism model shows a significant decrease in the number of solitary social interactions and the number of interactive vocal social interactions compared to wild non-human primates.
[0013] The present invention also provides a non-human primate autism model prepared by the above construction method.
[0014] The present invention also provides the use of the non-human primate autism model in studying pervasive developmental disorder animal models.
[0015] The present invention also provides a group of sgRNAs specifically targeting the MECP2 gene, wherein the sgRNA sequences are SEQ ID NO.1 and / or SEQ ID NO.2;
[0016] The nucleotide sequence of SEQ ID NO.1 is: ACCACCACCAUCACCACCACU;
[0017] The nucleotide sequence of SEQ ID NO.2 is: CCUGGGGCUCAGGGGGGCUGG.
[0018] Compared with the prior art, the present invention has the following advantages and technical effects:
[0019] The present invention adopts marmosets to construct a non-human primate autism model, and utilizes the advantages of the short breeding period of marmosets and the ability of marmosets to breed twins and triplets, thereby realizing a research method of directly comparing experimental subjects with the same genetic conditions after regulation; secondly, marmosets have a rich variety of calls, and the marmosets can flexibly use their different types of calls to transmit information and socially communicate among family members and between companions. The one-on-one call communication behavior is analogous to the characteristic of human conversation behavior, and a method for constructing a non-human primate autism model is established based only on the obvious characteristic that autistic marmosets have language communication disorders, thereby overcoming the defects of the non-human primate autism model construction that still exists in the prior art.
[0020] The method for constructing a non-human primate autism model described in the present invention uses CRISPR-Cas9 gene editing technology to inject AAV adeno-associated virus into the prefrontal region of the brain to knock out the methylated CpG binding protein 2 (MECP2) gene. The MECP2 gene mainly has an important influence on the learning and memory ability of mammals. Point mutations, duplications or deletion mutations of the MECP2 gene can lead to developmental neuropsychiatric diseases such as Rett syndrome and autism. The present invention induces marmosets to produce the core symptom of autism spectrum disorder - language communication disorder by knocking out the MECP2 gene, and uses vocal behavioral tests on marmosets to evaluate autistic language communication disorders.
[0021] The construction method of the present invention showed consistent and repeatable results in multiple marmoset experimental individuals. The present invention provides a new idea for selecting model animals for studying pervasive developmental disorders in animals. The marmoset autism model established by the present invention can be used as an important tool for studying the pathogenesis of autism and drug screening, and is of great significance for deepening the understanding of autism and providing new approaches for treatment and intervention. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0023] Figure 1 This is the design diagram of the sgRNA vector;
[0024] Figure 2 Schematic diagram of virus injection in the prefrontal lobe of the marmoset brain, where A is a 7T magnetic resonance scan structural image of the marmoset brain, B is a map of the prefrontal lobe of the marmoset brain, with a scale of 1 mm, C is a cross section at 15 mm from the interaural line, with a scale of 1 mm, D is a cross section at 16 mm from the interaural line, with a scale of 1 mm, and E is a cross section at 17 mm from the interaural line, with a scale of 1 mm;
[0025] Figure 3 Schematic diagram of the marmoset individual call and interactive call test, where A is the individual call test and B is the interactive call test;
[0026] Figure 4 The figures are statistical diagrams of the number of calls of marmosets in individual and interactive call tests, among which A is the number of response calls of marmosets in the experimental group before and after injection, B is the number of spontaneous calls of marmosets in the experimental group before and after injection, C is the number of solitary calls of marmosets in the experimental group before and after injection, D is the number of response calls of marmosets in the control group before and after injection, E is the number of spontaneous calls of marmosets in the control group before and after injection, and F is the number of solitary calls of marmosets in the control group before and after injection, *p<0.05, **p<0.01;
[0027] Figure 5 These are immunostaining images of the prefrontal lobe sections of the marmosets in the control group, where A is the immunostaining image of the control group, with a scale of 100 μm, B is the nuclear staining, with a scale of 50 μm, C is the injection position of GFP fluorescent protein, with a scale of 50 μm, D is the expression of MECP2 gene protein, with a scale of 50 μm, and E is the result of the combined staining, with a scale of 50 μm;
[0028] Figure 6 These are immunostaining images of the prefrontal lobe sections of marmosets in the experimental group, where A is the immunostaining image of the experimental group, with a scale of 100 μm, B is the nuclear staining, with a scale of 50 μm, C is the injection position of GFP fluorescent protein, with a scale of 50 μm, D is the expression of MECP2 gene protein, with a scale of 50 μm, and E is the result of the combined staining, with a scale of 50 μm;
[0029] Figure 7 This is a schematic diagram of the three-box social experiment;
[0030] Figure 8 The above are statistical graphs of the time that marmosets spend in their companions' boxes. A is the statistical graph of the time that marmosets in the experimental group spend in their companions' boxes, and B is the statistical graph of the time that marmosets in the control group spend in their companions' boxes. *p<0.05, ns means no significant difference.
[0031] Fig. 9 The movement trajectories of the experimental group marmosets and the control group marmosets in the cage;
[0032] Fig.10 The above are statistical graphs showing the percentage of time that marmosets spend in the upper part of the cage. A is the percentage of time that marmosets in the experimental group spend in the upper part of the cage, and B is the percentage of time that marmosets in the control group spend in the upper part of the cage. **p<0.01, ns means no significant difference. DETAILED DESCRIPTION
[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0034] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0038] Example 1
[0039] Sources of experimental supplies and instruments:
[0040] AAV9-hSyn-SaCas9-U6-sgMECP2-a virus, AAV9-hSyn-SaCas9-U6-sgMECP2-b virus and AAV9-hSyn-GFP virus were packaged by the Virus Production Center of Shanghai Institute of Neuroscience and provided by the laboratory of Professor Qiu Zilong of Shanghai Institute of Neuroscience, Chinese Academy of Sciences.
[0041] The microinjection pump was purchased from KD Scientific, the injection needle was purchased from Hamilton, the Opmi 6 surgical microscope was purchased from Zeiss, Germany, the cover glass and slides were purchased from Sigma, the fluorescence microscope VS120 was purchased from Olympus, and the confocal microscope A1 was purchased from Nikon.
[0042] Sodium pentobarbital was purchased from Jurox, North Kansas City, USA, PBS solution was purchased from biosharp, primary antibody was purchased from cell signaling, fluorescent secondary antibody was purchased from cell signaling, DAPI was purchased from Invitrogen, alfaxone was purchased from Jurox, Australia, atropine was purchased from Suzhou Kunchen Biotechnology, buprenorphine was purchased from East China Pharmaceutical Company, paraformaldehyde was purchased from biosharp, 0.01 M citrate buffer was purchased from targetretrieval, and BSA blocking solution was purchased from solarbio.
[0043] The requirements and sources of experimental animals are shown in Table 1:
[0044] Table 1 Requirements and sources of experimental animals
[0045] Group Age (month) gender Virus Control group 12 female gRNA (empty) Control group 12 male gRNA (empty) Control group 14 male gRNA (empty) Control group 17 male gRNA (empty) Experimental Group 11 female gRNA(MECP2) Experimental Group 9 female gRNA(MECP2) Experimental Group 11 male gRNA(MECP2) Experimental Group 9 male gRNA(MECP2) Experimental Group 16 male gRNA(MECP2)
[0046] All marmosets were provided by Gao Lixia's laboratory at Zhejiang University.
[0047] All experimental procedures in this paper were approved by the Animal Care Committee of Zhejiang University and followed the guidelines of the National Institutes of Health.
[0048] 1. Behavioral testing of experimental marmosets before virus injection
[0049] 1. Social testing of individual calls and interactive calls
[0050] In order to detect the success of the autism model construction before and after the injection of AAV-SaCas9-MECP2 knockout virus solution in the prefrontal lobe of marmosets, a vocal social test was designed, which was a single situational vocal test and an interactive vocal social test. The data were recorded five days before and after the injection of AAV-SaCas9-MECP2 knockout virus solution in the prefrontal lobe of the marmoset brain. The specific operation is as follows:
[0051] (1) Single scenario call test
[0052] At a fixed time every day, each marmoset in the experimental group was transferred to the recording room, and the marmosets in the control group in the same cage remained in the original position, and the recording was performed for 10 min.
[0053] (2) Interactive call test
[0054] At a fixed time every day, each experimental group of marmosets and their caged control group marmosets were transferred to the recording room for 10 min of recording.
[0055] The audio recordings were made using an Audio-Technica AT2020 directional condenser microphone and a Roland rubix22 sound card, and the sounds of marmosets were collected using Adobe Audition software for data preservation.
[0056] 2. Three-box social behavior detection
[0057] Three boxes are specially made for marmosets because of their strong mobility and jumping ability. Figure 7 ), with a size of 120cm×60cm×60cm, and is divided into three areas (left, middle, and right) inside, where marmosets can move freely. The marmosets were transferred from the monkey house to the laboratory at a fixed time every day. The marmosets entered the three boxes on their own and were allowed to adapt and explore for 20 minutes. After that, toys were placed in a fixed position on the left side of the box, and cagemates were placed in a fixed position on the right side of the box without interfering with the marmosets' vision, smell, hearing, and touch. The behavior of the experimental animals was recorded by a video recorder for 10 minutes.
[0058] After the experiment, the marmosets were returned to the transfer box, put back in the monkey cage and given food rewards, and the experimental equipment was thoroughly cleaned, disinfected and deodorized to prevent interference with the next experiment.
[0059] 3. Detection of monkey cage activities
[0060] At a fixed time every day, the marmosets were transferred from the living cage to the video cage. The video cage and the living cage were similar in material and size. The video cage was more spacious than the living cage, which was convenient for recording the daily behavior of the experimental subjects. After the marmosets entered the video cage, any human interference that could affect the animal's behavior was avoided. The experiment lasted for 10 minutes, and the video recorder continuously recorded the experimental animal's behavior.
[0061] 2. Locate the prefrontal area
[0062] The brain structure of individual marmosets was obtained by scanning using 7T magnetic resonance imaging technology. The specific process is as follows:
[0063] (1) Marmosets were fasted for 8 h before the experiment to prevent reflux and aspiration of contents during anesthesia.
[0064] (2) Alfaxalone was injected intramuscularly in the thigh for anesthesia. The dosage of alfaxalone was calculated based on the body weight of the marmoset, 0.1 mg / kg. Atropine was injected intramuscularly at the same time. The dosage of atropine was calculated based on the body weight of the marmoset, 0.045 mg / kg, to reduce saliva secretion.
[0065] (3) After induction of anesthesia, the animal was fixed on a MRI-compatible stereotaxic apparatus. First, an ear bar was inserted into the ear canal for preliminary fixation. The position was adjusted to ensure the stability of the head. Then the mouth bar was adjusted to assist fixation and the lower edge of the eyelid and the ear bar were kept at the same level as much as possible. A glass cannula with a diameter of 1 mm filled with lidocaine gel was placed on the track in the center of the ear bar to determine the position of the interaural line. Then, the animal was transferred to the scanning room and connected to the isoflurane gas anesthesia line to maintain anesthesia. Finally, the monitoring instrument of blood oxygen, heart rate, body temperature and vital signs was connected, and a water bath blanket was connected to maintain the animal's body temperature during the experiment. A scanning coil was placed on the head to obtain a clear image of the marmoset brain structure with a clear interaural line mark, so as to achieve accurate positioning of the prefrontal lobe. After the scan was completed, the marmoset was transferred to the electric blanket in the transfer box and waited for full awakening.
[0066] 3. Virus injection into target brain area
[0067] It mainly includes preparation before injection, virus liquid injection, recovery and care after injection. The specific process is as follows:
[0068] (1) Preparation before injection: AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution (titer 1.12×10 13 VG / mL), AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution (titer is 1.64×10 13 VG / mL) and AAV9-hSyn-GFP virus solution (titer was 2.18×10 13VG / mL) were mixed at a volume ratio of 4:4:2 to obtain AAV-SaCas9-MECP2 knockout virus solution. AAV9-hSyn-SaCas9-U6-sgMECP2-a and AAV9-hSyn-SaCas9-U6-sgMECP2-b target different sgRNA target sequences, respectively. The sgRNA target sequence of AAV9-hSyn-SaCas9-U6-sgMECP2-a is: ACCACCACCATCACCACCACT (SEQ ID NO.3), and the sgRNA target sequence of AAV9-hSyn-SaCas9-U6-sgMECP2-b is: CCTGGGGCTCAGGGGGGCTGG (SEQ ID NO.4). The sgRNA sequences are SEQ ID NO.1 and SEQ ID NO.2, and the nucleotide sequence of SEQ ID NO.1 is: ACCACCACCATCACCACCACT; the nucleotide sequence of SEQ ID NO.2 is: CCTGGGGCTCAGGGGGGCTGG, and AAV9-hSyn-GFP green fluorescent protein is used to indicate the injection site. The mixed virus solution was extracted into a 10 μL injection needle through a microinjection pump, and then placed on ice for later use. MRIcron was used to calculate the position of the target injection brain area based on the MRI structural image, and the position of the interaural line was determined based on the imaging position of the glass cannula filled with lidocaine gel in step 2, and then the anterior-posterior (AP), left-right (ML) and up-down (DV) coordinates of the interaural line were calculated based on this combined with the marmoset brain atlas. It was bilateral hemisphere, with three AP planes in each hemisphere, 15 mm, 16 mm and 17 mm forward of the interaural line (marmoset brain atlas AP15, AP16, AP17), one injection point on each AP plane, and each injection point was divided into three depth injections, at 1.5 mm, 2.5 mm and 3.5 mm, respectively, and 1 μL was injected at each depth.
[0069] (2) Virus injection:
[0070] The prefrontal region of the marmosets in the experimental group was injected with AAV-SaCas9-MECP2 knockout virus solution, and the prefrontal region of the marmosets in the control group was injected with a mixture of empty virus and AAV9-hSyn-GFP virus. The volume ratio of the empty virus and AAV9-hSyn-GFP virus solution in the mixture was 8:2.
[0071] Under sterile conditions, the scalp was opened, the connective tissue was cleaned, and a skull drill was used to open a window according to the positioning. During the entire operation, the vital signs of the marmoset should be paid attention to to prevent heavy bleeding. The bone chips were rinsed with saline and the rest of the skull was kept moist. Three injections were made at a depth of 1 mm at each site, and 1 μL of virus was injected at each depth. The injection needle was fixed on the micromanipulator of the stereotaxic instrument, and the injection needle was slowly inserted into the brain tissue under the microscope. After reaching the target depth of 1.5 mm, the needle was stopped for 2 minutes to allow the injection needle and brain tissue to fully fit, and then the virus solution was injected at a rate of 150 nL / min. After the injection was completed, the needle was stopped for 2 minutes and then the needle was pulled out to prevent the virus from overflowing. The injection of all sites on both sides of the brain was completed according to this process. After the injection was completed, the saline was rinsed and the removed skull was put back in place and fixed with bone wax, and the scalp was sutured with sutures. After the marmosets woke up, buprenorphine (0.005 mg / kg) was injected into the thigh muscle for analgesia, followed by an injection of cephalexin (22 mg / kg) into the thigh muscle to prevent infection.
[0072] (3) Recovery and care after injection
[0073] Anesthesia and vital sign monitoring were withdrawn. After the marmoset regained consciousness, it was placed on an electric blanket in an incubator and given a cephalosporin (22 mg / kg) injection into the thigh muscle for seven consecutive days to prevent infection. The marmoset was weighed and its temperature was measured to confirm its condition. One week later, the marmoset returned to normal.
[0074] 4. Behavioral testing of experimental marmosets after virus injection
[0075] 1. Social testing of individual calls and interactive calls
[0076] Counting from the injection of the virus solution, 8 weeks later, when the virus was expressed, the marmosets were retested for behavioral testing. The specific process is as follows:
[0077] (1) Single scenario call test
[0078] At a fixed time every day, each marmoset in the experimental group was transferred to the recording room, and the marmosets in the control group in the same cage remained in the original position, and the recording was performed for 10 min.
[0079] (2) Interactive call test
[0080] At a fixed time every day, each experimental group of marmosets and their caged control group marmosets were transferred to the recording room for 10 min of recording.
[0081] 2. Three-box social behavior detection
[0082] Three boxes are specially made for marmosets because of their strong mobility and jumping ability. Figure 7), with a size of 120cm×60cm×60cm, and is divided into three areas (left, middle, and right) inside, where marmosets can move freely. The marmosets were transferred from the monkey house to the laboratory at a fixed time every day. The marmosets entered the three boxes on their own and were allowed to adapt and explore for 20 minutes. After that, toys were placed at fixed positions on the left side of the box, and cagemates were placed at fixed positions on the right side of the box without interfering with the marmosets' vision, smell, hearing, and touch. The behavior of the experimental animals was recorded by a video recorder for 10 minutes.
[0083] After the experiment, the marmosets were returned to the transfer box, put back in the monkey cage and given food rewards, and the experimental equipment was thoroughly cleaned, disinfected and deodorized to prevent interference with the next experiment.
[0084] 3. Detection of monkey cage activities
[0085] At a fixed time every day, the marmosets were transferred from the living cage to the video cage. The video cage and the living cage were similar in material and size. The video cage was more spacious than the living cage, which was convenient for recording the daily behavior of the experimental subjects. After the marmosets entered the video cage, any human interference that could affect the animal's behavior was avoided. The experiment lasted for 10 minutes, and the video recorder continuously recorded the experimental animal's behavior.
[0086] 5. Data Analysis and Statistics
[0087] The behavioral data of marmosets were mainly compared before and after virus injection and between the experimental group and the control group. The behavioral differences were analyzed to further evaluate the success of the autism model.
[0088] The results are as follows Figure 4 As shown, Figure 4 A in the figure is the number of response calls of the marmosets in the experimental group before and after injection. The number of response calls after injection was significantly reduced compared with the number of response calls before injection. Figure 4 B in the figure is the number of spontaneous calls of marmosets in the experimental group before and after injection. The number of spontaneous calls after injection did not decrease significantly according to statistical tests. Figure 4 Middle C is the number of solitary calls of the experimental group marmosets before and after injection. The number of solitary calls after injection was significantly reduced compared with the number of solitary calls before injection; Figure 4 Middle D shows that there was no significant difference in the number of response calls of the control marmosets before and after injection; Figure 4 Middle E: There was no significant difference in the number of spontaneous calls of the control marmosets before and after injection; Figure 4 F in the figure shows that there was no significant difference in the number of solitary calls of the control marmosets before and after injection. From the analysis of the marmosets in the experimental group, the injection of AAV-SaCas9-MECP2 knockout virus solution obviously caused the appearance of the autism language communication disorder phenotype in the marmosets, and the marmoset autism language communication disorder model was obtained. Combined with the analysis of the marmosets in the control group, it was proved that the mixture of empty virus and AAV9-hSyn-GFP virus and the injection operation would not affect the behavior of the marmosets.
[0089] The results of the time percentage of the experimental group and the control group marmosets in the companion box, the movement trajectory in the cage, and the time percentage in the upper part of the cage before and after the virus injection are as follows: Figure 8 , 9 and 10 shown by Figure 8 According to the records, after the marmosets in the experimental group were injected with the virus, the proportion of time they spent in the companion box decreased significantly compared with before the injection. Fig. 9 According to the records, after the virus was injected, the movement trajectory of the marmosets in the experimental group changed significantly, and they tended to move in the upper part of the cage. Fig.10 It can be seen that the proportion of time that the marmosets in the experimental group spent exercising in the upper part of the cage increased significantly after injection.
[0090] Experimental Example 1
[0091] Experiment to verify the transfection effect of AAV virus in the prefrontal cortex of marmoset brain
[0092] After the injection of marmosets, the virus was expressed for more than 8 weeks, and 2 marmosets were randomly selected from the experimental group and the control group for perfusion and brain extraction. They were given 80 mg / kg of sodium pentobarbital, perfused with 0.9% saline and then 4% paraformaldehyde. After the perfusion, the brain was removed and placed in a 4% paraformaldehyde solution and placed in a 4°C refrigerator for fixation for more than 12 hours.
[0093] After the brain was fixed, it was placed in a 30% sucrose PBS solution and stored in a 4°C refrigerator for dehydration. After the marmoset brain was completely sunk to the bottom of the sucrose solution, it was frozen at -80°C for 3 minutes and sliced. The slice thickness was 20 μm. The sliced brain slices were placed in antifreeze (mixed in a volume ratio of PBS: glycerol: ethylene glycol of 4:3:3) and stored at -20°C.
[0094] Before staining, brain slices were placed at 40°C for 30 min to rewarm, and then immersed in PBS solution for 30 min. Brain slices were immersed in 0.01 M citrate-hydrochloric acid buffer and placed in a 95°C water bath for 30 min for antigen retrieval.
[0095] After the repair is completed, place it in a light-proof humidified box to cool down, use PBST to prepare 5% BSA blocking solution (mixed by volume, donkey serum 5%: triton 0.3%: carrageenan 0.125%: PBS 94.575%), add it to the area where the brain slice is located, and block it at 26℃ for 1h. Then use the blocking solution to prepare the primary antibody reaction solution (rabbit mAb and BSA blocking solution are prepared at a volume ratio of 1:500) and add it to the area where the brain slice is located. After the brain slice is immersed in the primary antibody reaction solution and reacted at room temperature for 2h, it is washed 3 times with PBS, each time for 10min.
[0096] The corresponding fluorescent secondary antibody (Alexa Fluor 555 / 647, 1:500) was prepared with blocking solution and added to the brain slices for reaction at 26°C for 2 hours. After the reaction, the brain slices were washed with PBS for 3 times, 10 minutes each time.
[0097] Finally, DAPI (4',6-diamidino-2-phenylindole, used for staining live and fixed cells) (1:5000) was used for nucleus staining for 5 min, and then washed with PBS for 3 times, 10 min each time. The slides were sealed with coverslips and sealing agents, dried, and stored in a light-proof brain slide box at 4°C.
[0098] The data of the stained images were acquired by fluorescence microscope VS120 and confocal microscope A1. ImageJ software was used for data processing and drawing.
[0099] The results are as follows Figure 5 and Figure 6 As shown, DAPI shows the stained nuclei of the cells here, and the stained cells are shown in blue; GFP green fluorescent protein shows the location of virus injection; red indicates the protein expressed by MECP2. Figure 5 and Figure 6 By comparison, it can be seen that the expression level of MECP2 in marmosets in the experimental group was lower than that in the control group, indicating that the gene knockout was effective.
[0100] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A method for constructing a non-human primate autism model, characterized in that: The following steps are involved: (1) locating the prefrontal lobe region of a non-human primate; (2) injecting an AAV-SaCas9-MECP2 knockout virus solution into the prefrontal lobe region of the brain in step (1); (3) performing a behavioral test on the non-human primate 8 weeks after the injection of the AAV-SaCas9-MECP2 knockout virus solution; The non-human primate is a marmoset; The positioning in step (1) uses 7T magnetic resonance scanning imaging technology; The injection depth in step (2) is 1.5 to 3.5 mm, the injection speed is 150 nL / min, and there are 6 injection points; The behavioral tests described in step (3) are individual situation social interaction and interactive vocalization social interaction tests.
2. The construction method according to claim 1, characterized in that: The AAV-SaCas9-MECP2 knockout virus solution in step (2) includes AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution, AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution and AAV9-hSyn-GFP virus solution; the injection volume of the AAV-SaCas9-MECP2 knockout virus solution at each injection point is 3 μL.
3. The construction method according to claim 2, characterized in that: The volume ratio of AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution, AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution and AAV9-hSyn-GFP virus solution in the AAV-SaCas9-MECP2 knockout virus solution is 4:4:2; the titer of the AAV9-hSyn-SaCas9-U6-sgMECP2-a virus solution is 1.12×10 13 VG / mL; the titer of the AAV9-hSyn-SaCas9-U6-sgMECP2-b virus solution is 1.64×10 13 VG / mL; the titer of the AAV9-hSyn-GFP virus solution is 2.18×10 13 VG / mL.
4. The construction method according to claim 1, characterized in that: The non-human primate autism model shows a significant decrease in the number of solitary social calls and the number of interactive social calls compared to wild non-human primates.
5. Use of the construction method according to any one of claims 1 to 4 in preparing a non-human primate autism spectrum disorder model.
